Response to Dr Jeyaraj
Journal of Perinatology (2007) 27, 395-396; doi:10.1038/sj.jp. 7211740 We have read with interest the comments made by Dr Jeyaraj on cyclo-oxygenase inhibition for tocolysis and its effect on the neonate. 1 We appreciate learning that nimesulide use as a tocolytic has been associated with irreversible renal failure in infants. It is comforting to know that nimesulide has not been approved for marketing in the United States, United Kingdom, Australia or Canada. 2 In regard to our recent study (Cordero et al. 3 ), we noted that serum creatinine levels from 58 premature infants exposed to antenatal indomethacin, and those from 58 control showed similar values at birth, comparable increases during the second and third day and progressive declines to baseline levels during the following 2 weeks. In our series, only two infants from each group showed significant, albeit temporary oliguria. No cases of irreversible renal failure occurred in either group of infants.
Our observations are not unexpected because creatinine levels are known to rise dramatically but temporarily during the first 2 days of life in premature infants never exposed to antenatal or postnatal indomethacin (Miall et al. 4 ). It is also known that exposure to antenatal indomethacin is associated with elevated serum creatinine levels that will return to baseline after 2 to 3 weeks of life (Butler-O'Hara and D'Angio 5 ). Postnatal treatments for patent ductus arteriosus with indomethacin are also known to decrease renal blood flow with elevated serum creatinines and in some cases oliguria, but without irreversible renal damage (Fowlie and Davis 6 ). In all, we believe that a short course of antenatal indomethacin tocolysis when indicated and at standard doses should not result in significant renal insufficiency and more importantly irreversible renal failure.
